Satellos Bioscience Inc. balance sheet MSLE

Annual Quarterly

As of Dec 31, 2025, Satellos Bioscience Inc. had total assets of $31.9 million and total liabilities of $4.1 million. Stockholders' equity was $27.8 million. Cash and investments were $9.8 million. The current ratio, current assets divided by current liabilities, was 7.77.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line
FY 2025
Dec 31, 2025
Assets
Cash
10
Cash and investments
10
Total current assets
32
Property and equipment, net
0
Total assets
32
Liabilities and equity
Accounts payable
4
Total current liabilities
4
Total liabilities
4
Stockholders' equity
28
Ratios
Current ratio
7.77x
Return on equity
-89.52%
Return on assets
-78.00%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
MSLE (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Canada (Federal Level)
Headquarters
Markham
SEC filer status
, Emerging growth company
SEC CIK
1421642
Former names
ICO THERAPEUTICS INC (until Sep 10, 2019)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.